Division Nutrition and Diabetes Sirio Libanés Hospital Buenos Aires Argentina.
SANOFI Buenos Aires Argentina.
Endocrinol Diabetes Metab. 2020 Oct 31;4(1):e00164. doi: 10.1002/edm2.164. eCollection 2021 Jan.
To describe in a real-world setting, the proportion of patients with a symptomatic hypoglycaemic event and the proportion of individuals with type 2 diabetes, who newly or recently initiated with basal insulin, achieving individual or general HbA1c target.
DINAS-AR was a national prospective observational study to assess the unmet needs in patients with type 2 diabetes treated with basal insulin with or without oral antihyperglycaemic drugs and/or GLP-1 receptor agonist. The study was conducted at 19 hospitals.
A total of 385 uncontrolled patients (≥18 years) who recently initiated basal insulin or who initiated treatment within a year prior to study enrolment entered the study. Outcomes were follow-up incidence of hypoglycaemic events, change of HbA1C and achievement of HBA1c <7% or individual target. A total of 44 patients (11.9%) reported the occurrence of ≥1 symptomatic hypoglycaemia event(s). HbA1c reductions were greater in patients who had recently initiated treatment with basal insulin (between 15 and 90 days prior to study entry) vs patients who initiated treatment within 1 year. A total of 80 patients (31.6%) achieved individual HbA1c target (or target <7.0%) at Week 24. Furthermore, the proportion of patients achieving this target without symptomatic hypoglycaemia was 26.1% (n = 66). A lower percentage of glycemia target achievement was observed in patients reporting hypoglycaemia (n = 14), 20.6% of all patients reporting hypoglycaemia event(s) vs (n = 66) 35.7% of all patients without hypoglycaemia event reported.
In this real-world study, although the hypoglycaemia rate was not high in adults with type 2 diabetes treated with insulin, there was a lower percentage of patients that achieved glycemic target among those reporting hypoglycaemia events vs patients who did not report them.
在真实环境中描述新诊断或近期开始接受基础胰岛素治疗的 2 型糖尿病患者中，出现症状性低血糖事件的患者比例和达到个体或总体糖化血红蛋白（HbA1c）目标的个体比例。
DINAS-AR 是一项全国性的前瞻性观察性研究，旨在评估正在接受基础胰岛素联合或不联合口服降糖药和/或 GLP-1 受体激动剂治疗的 2 型糖尿病患者的未满足需求。该研究在 19 家医院进行。
共有 385 名未控制的患者（≥18 岁）入组，这些患者最近开始接受基础胰岛素治疗，或在研究入组前一年内开始治疗。研究的结局是低血糖事件的随访发生率、HbA1c 的变化以及达到 HbA1c<7%或个体目标的情况。共有 44 名患者（11.9%）报告发生≥1 次症状性低血糖事件。与在研究入组前 15 至 90 天开始基础胰岛素治疗的患者相比，在 1 年内开始治疗的患者的 HbA1c 降低幅度更大。共有 80 名患者（31.6%）在第 24 周达到了个体 HbA1c 目标（或目标<7.0%）。此外，无症状低血糖患者达到该目标的比例为 26.1%（n=66）。在报告低血糖的患者中，达到血糖目标的比例较低（n=14），所有报告低血糖事件的患者中为 20.6%，而所有无低血糖事件报告的患者中为 35.7%。
在这项真实世界研究中，尽管接受胰岛素治疗的 2 型糖尿病成人的低血糖发生率不高，但在报告低血糖事件的患者中，达到血糖目标的患者比例低于未报告低血糖事件的患者。
